Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Prostatic Neoplasms 142Breast Neoplasms 97Lung Neoplasms 72Brain Neoplasms 67Glioblastoma 59Carcinoma, Non-Small-Cell Lung 54Glioma 52Pancreatic Neoplasms 39Neoplasms 39Neoplasm Metastasis 36Colorectal Neoplasms 31Carcinoma, Hepatocellular 30Lymphoma, Large B-Cell, Diffuse 27Carcinoma, Renal Cell 27Multiple Myeloma 26Squamous Cell Carcinoma of Head and Neck 25Rectal Neoplasms 21Melanoma 21Ovarian Neoplasms 20Astrocytoma 20Urinary Bladder Neoplasms 18Lymphoma, Follicular 18Uterine Cervical Neoplasms 17Colonic Neoplasms 17Head and Neck Neoplasms 16Lymphoma 15Esophageal Neoplasms 15Sarcoma 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell 14

Interventions

pembrolizumab 2cabozantinib 2veliparib 1olaparib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1Temozolomide 1Specimen Handling 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Nivolumab 1Mesna 1Magnetic Resonance Spectroscopy 1Gefitinib 1Cyclophosphamide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adrenal Cortex Neoplasms × Magnetic Resonance Spectroscopy × Clear all
NCT06006013 2026-02-18

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Emory University

Phase 2 Recruiting
21 enrolled
Endocrine

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡